Mr. Peter Llewellyn-Davies is a Founder of Accellerate Partners, focused on executing change and supporting private and listed companies and advising venture capital and private equity firms. Mr. Llewellyn-Davies served as the Chief Financial Officer and Member of Executive Management Board at MediGene AG from October 1, 2012 to March 31 2016. Mr. Llewellyn-Davies is a strategic Chief Financial Officer with an over 25 year track record in international M&A deals, company turnarounds, licensing transactions and financing activities with particular experience in chemical and healthcare industries. Mr. Llewellyn-Davies served as the Chief Financial Officer and Member of the Executive Board at Wilex AG from September 1, 2006 to August 31, 2012. Prior to this, he served as Managing Director of Müller Dairy (UK) and Executive Finance Director at Süd-Chemie AG, where he oversaw the international expansion of the Munich-based company. Mr. Llewellyn-Davies served as the Chief Financial Officer of CoreOptics GmbH. He served as the Chief Financial Officer of a UK based production company and served top level positions for SMEs as well as a large international group in Germany. His career began at a UK investment bank and served in various board seats in companies around the globe. He has been Non-Executive Director of Shield Therapeutics plc. since February 26, 2016. He serves as a Non Executive Director of Immunocore Limited. He has been Member of Supervisory Board at Sygnis AG since July 10, 2017. Mr. Llewellyn-Davies read business management, banking, marketing and controlling in London, St. Gallen and Munich and has a certificate in business studies from the University of London.

Business